SAN DIEGO, January 9, 2020 – Meet Antonius Schuh, Ph.D. (CEO) and Andreas Klostermann, Ph.D. (CSO) for an update on selectION’s best-in-class ion channel blockers and the status of the pre-clinical work.
Site Search
Recent News
- selectION, Inc., Reports Interim Safety and Tolerability Results of Phase 1b Clinical Trial in Atopic Dermatitis
- Meet selectION, Inc. at the BIO International Convention in Boston, on June 5th to 8th, 2023
- Meet selectION, Inc. at the BIO-EUROPE SPRING Conference in Basel, Switzerland, on March 20th to March 22nd, 2023